Lynparza recommended for approval in the EU by CHMP for BRCA-mutated metastatic castration-resistant prostate cancer
Only PARP inhibitor to improve overall survival vs. new hormonal agent treatments in advanced prostate cancerAstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for patients with metastatic castration-resistant prostate cancer (mCRPC) with breast cancer susceptibility gene 1/2 (BRCA1/2) mutations, a subpopulation of homologous recombination repair (HRR) gene mutations. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on a subgroup analysis of patients